Effect Of Xuezhikang Capsule On PCSK9 And HsCRP In Patients With ASCVD

Objectives: To evaluate the effect of Xuezhikang capsule on PCSK9 and hsCRP in patients with ASCVD,and to observe the efficacy of Xuezhikang capsule.Methods: From April 2018 to December 2018,a total of 60 patients with ASCVD were enrolled from inpatient and outpatient of department of cardiology in the Second Affiliated Hospital of Nanjing Medical University.The fasting blood tests were performed for TG,TC,LDL-C,HDL-C,and creatinine,CK,hsCRP and other indicators.Circulation PCSK9 concentrations were determined by ELISA assay.Patients were randomized into a Xuezhikang group(0.6g bid,twice a day)or a rosuvastatin group(10 mg qd).After 4 weeks,the above indicators were reexamed again.Adverse reactions were recorded.RESULTS: Sixty patients met the inclusion criteria and 58 patients were eventually followed up.After 4 weeks of treatment,TC and LDL-C in Xuezhikang group decreased from 4.27±1.33mmol/L and 3.23±0.71mmol/L to 3.75±0.95mmol/L and 3.05±0.65mmol/L,respectively.Rosuvastatin group TC and LDL-C decreased from 4.44±0.95mmol/L and 3.02±0.75mmol/L to 3.91 ± 0.69mmol/L and 2.78±0.62mmol/L,respectively,and the differences were statistically significant(P<0.05).The TG of Xuezhikang group decreased from 1.72±0.93mmol/L to 1.66±0.79mmol/L,and the difference was not statistically significant(P>0.05).The TG of rosuvastatin group decreased from 1.55±0.84mmol/L to 1.37±0.51mmol/L,the difference was statistically significant(P<0.05).The HDL-C of Xuezhikang group increased from 1.09±0.18mmol/L to 1.12±0.17mmol/L,the difference was statistically significant(P<0.05).The HDL-C of rosuvastatin group increased from 1.17±0.75mmol/L to 1.18±0.29mmol/L,the difference was not statistically significant(P>0.05).The PCSK9 of Xuezhikang group and rosuvastatin group increased from 112.88±17.22ng/ml and 115.56±16.33ng/ml to 126.87±16.98ng/ml and 143.13±24.31ng/ml,respectively.The effects of the two groups of drugs on PCSK9 were statistically significant(P<0.05).At the same time,the level of PCSK9 was higher in the rosuvastatin group than in the Xuezhikang group(P<0.05).The hsCRP of the two groups decreased from 2.75±2.58mg/L and 2.34±2.17mg/L before treatment to 2.04±1.99mg/L and 1.26±1.00mg/L,respectively.Both groups were shown to have an effect on the change of hsCRP(P<0.05).Baseline PCSK9 was positively correlated with TC and had no correlation with other lipid indicators.The effect of two groups on creatinine and transaminase was little,and the difference was not statistically significant(P>0.05).Conclusion: Xuezhikang capsule and rosuvastatin can reduce LDL-C and increase PCSK9 levels in ASCVD patients after 4 weeks,but the increment of PCSK9 is lower than that of rosuvastatin.Xuezhikang and rosuvastatin can reduce hsCRP in ASCVD patients.This study suggests that Xuezhikang capsule also has the effect of lowering LDL-C when it is unable to tolerate high-intensity statins(rosuvastatin),and has little effect on PCSK9.